 BetterLife Pharma Incs bid to advance its TD-010 candidate to treat chronic anxiety and depression has been boosted by a funding award. The biotech revealed it had been granted Mitacs Accelerate program funding for its joint application with Dr Argel Aguilar-Valles at Carleton University department of neuroscience to carry out research of the drug in preclinical models. 